Abstract: Embodiments of the invention are generally directed to lignin-modifying enzymes and systems and methods of their manufacture. In many embodiments, yeast strains, including S. cerevisiae, are used to produce and secrete lignin-modifying enzymes Further embodiments are directed to methods to screening peroxidase-producing yeast strains, including S. cerevisiae. Additional embodiments are directed to an expression vector or cassette encoding for a protein of interest and one or more proteins to allow for surface to display of the protein of interest.

Abstract: The present disclosure relates to engineered microbial cells that have been engineered to include a uricase, a uric acid transporter, or both a uricase and a uric acid transporter. The engineered microbial cells of the present disclosure are useful in degrading uric acid inside the engineered microbial cell. The engineered microbial cells of the present disclosure are useful in methods of treating hyperuricemia. The engineered microbial cells of the present disclosure are also useful in methods of treating gout, and in particular chronic refractory gout.

Abstract: The present invention relates to a method for producing a recombinant polypeptide of interest in a microbial host cell, comprising (a) introducing a polynucleotide encoding the polypeptide of interest into a microbial host cell which has been modified such that an enzymatic activity selected from the group consisting of ketol-acid reductoisomerase (NADP(+)) activity (EC 1.1.1.86), acetohydroxyacid synthase activity (EC 2.2.1.6), aspartate kinase activity (EC 2.7.2.4), homoserine dehydrogenase activity (EC 1.1.1.3), and L-threonine dehydratase activity (EC 4.3.1.19) is modulated in said microbial host cell as compared to the enzymatic activity in an unmodified microbial host cell, and (b) expressing said polypeptide of interest in said microbial host cell. Moreover, the present invention relates to a method for reducing misincorporation of at least one non-canonical branched-chain amino acid into a recombinant polypeptide of interest expressed in a microbial host cell.

Abstract: The present invention relates to a novel human epidermal growth factor (hEGF)-trigger factor (TF) fusion protein and a use thereof. More particularly, the human epidermal growth factor (hEGF)-trigger factor (TF) fusion protein of the present invention has fused therein: a signal peptide of a Bacillus subtilis-derived xylanase; a human epidermal growth factor (hEGF); and an Escherichia coli-derived trigger factor (TF). Therefore, the present invention not only enhances the water solubility and expression rate of a target protein, but also notably enhances useful effects such as the effects of increasing skin cell growth and healing a wound, and thus may be widely used in various industries as an active ingredient for a functional cosmetic composition and a pharmaceutical composition.

Abstract: The present invention relates to a bacterium, in which the expression and/or the activity of surface proteases is/are inhibited, to its preparation process and to the uses of this bacterium.

Abstract: Processes for transesterifying wax esters. Implementations may include: providing a feedstock including wax esters, contacting the feedstock with a lipase, and catalytically transesterifying the wax esters in the feedstock with the lipase to form a transesterified product. An oxidative stability index (OSI) of the transesterified product may be greater than an OSI of the feedstock.

Abstract: The present disclosure relates to a method and a composition comprising an esterase for enzymatic surface modification of a polyester. The present disclosure also relates to a method of degradation or hydrolysis of an insoluble plant material.

Abstract: Disclosed herein are modified strains for reducing degradation of recombinantly expressed products secreted from a host organism and methods of using the modified strains. In some embodiments, to attenuate a protease activity in Pichia pastoris, the genes encoding enzymes the degrade proteases are inactivated or mutated to reduce or eliminate activity. In preferred strains, the protease activity of proteases encoded by PAS_chr4_0584 (YPS1-1) and PAS_chr3_1157 (YPS1-2) (e.g., polypeptides comprising SEQ ID NO: 66 and 67) is attenuated.

Abstract: The present invention relates to mannanase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: The disclosure discloses a cyclodextrin glycosyltransferase with enhanced solvent tolerance and preparation thereof, belonging to the technical fields of enzyme engineering and genetic engineering. The disclosure constructs four cyclodextrin glycosyltransferase mutants with enhanced organic solvent tolerance. Among them, the mutant with the optimal tolerance to DMSO and methanol is G539I/R146F/D147N, which is 1.6 times and 1.7 times higher than that of WT, respectively; the mutant with the optimal tolerance to ethanol is R146F, which is 1.4 times higher than that of WT; the mutant with the optimal tolerance to acetone is G539I/R146F, which is 1.5 times higher than that of WT. The disclosure helps to expand the application of glycosyltransferases in organic reaction systems, improves the enzymatic efficiency of CGTase on natural hydrophobic substrates, and has great application prospects.

Abstract: Disclosed herein is a method for alleviating osteoarthritis using a composition containing an isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557 which is deposited at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH under an accession number DSM 33617.

Abstract: The present disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides mutated Cas13 proteins and their use in modifying target sequences as well as mutated Cas13 nucleic acid sequences and vectors encoding mutated Cas13 proteins and vector systems or CRISPR-Cas13 systems.

Abstract: The invention provides an animal feed composition comprising microbial ?-amylase. The invention further provides methods of increasing the growth (weight gain), the average daily weight gain or the efficiency of feed utilization by an animal or reducing the number of days needed to achieve a desired weight in an animal, comprising feeding to the animal an animal feed composition of the present invention.

Abstract: The present invention provides a method for efficiently producing ethanol from a lignocellulosic raw material. More specifically, the present invention provides a method for producing ethanol from a lignocellulosic raw material, which comprises a step of performing multiple parallel fermentation while continuously or intermittently adding an additional saccharification enzyme to a fermentation liquid comprising a lignocellulosic raw material, a saccharification enzyme and a yeast so that the physical property value of the fermentation liquid itself is maintained within a preset range.

Abstract: Disclosed herein are glucosyltransferases with modified amino acid sequences. Such engineered enzymes have modified alpha-1,3-branching activity. Further disclosed are reactions and methods in which engineered glucosyltransferases can be used to add one or more alpha-1,3 branches to a suitable acceptor such as glucan.

Abstract: The disclosure belongs to the field of microorganisms, and in particular relates to a strain of Akkermansia muciniphila and a product and application thereof. The A. muciniphila is AKK PROBIO, with a preservation number of CGMCC No. 20955. AKK PROBIO of the disclosure has good tolerance, high safety, wide indications, and a good therapeutic effect, can prevent and treat diseases such as colitis, colorectal carcinoma, Alzheimer's disease, and gouty arthritis, and has very good clinical application prospects.

Abstract: The present disclosure relates to a synthesis method of ?-nicotinamide mononucleotide (?-NMN) and an intermediate thereof. In the present disclosure, phospholipid metabolism enzymes phospholipase D (PLD) and phospholipase C (PLC) widely present in the biosphere are used as catalysts to prepare ?-NMN through two-step enzymolysis or one-pot synthesis; and an intermediate, namely phosphatidyl nicotinamide riboside (PNR), is obtained during the two-step enzymolysis. The present disclosure has simple reaction steps, low production cost, and environmental friendliness, and is suitable for large-scale industrial production.

Abstract: Disclosed are methods and compositions for real-time monitoring cellular calcium ion dynamics by red-shifted genetically encoded indicators under optogenetic control, in which millisecond-timescale of temporal control of optical activation or inactivation and signal recording can be achieved. The methods include artifact-free functional imaging in conjunction with optogenetic tools for studying cellular physiology, signal transduction and neuronal activity. Thus, all-optical and non-invasive approaches for drug screening, toxicity testing and assessment of cell functions may be provided.

Abstract: An engineered clostridial neurotoxin comprising an activation loop that comprises an amino acid sequence of the formula Cys-(Xaa)a-Ile-Asp/Glu-Gly-Arg-(Yaa)b-Cys(SEQ ID NO: 1), wherein a is an integer from 1 to 10, b is an integer from 4 to 15, each iteration of Xaa and Yaa individually represents an amino acid, and the engineered clostridial neurotoxin is not BoNT/C1, a method for producing the same, a method of treating a disease or condition comprising administering the engineered clostridial neurotoxin or the corresponding di-chain clostridial neurotoxin, a composition comprising the engineered clostridial neurotoxin or the corresponding di-chain clostridial neurotoxin, and a polynucleotide encoding the engineered clostridial neurotoxin.

Abstract: Among the various aspects of the present disclosure is the provision of a biological and biochemical production of piperazic acid derived from the newly discovered production pathway for L-piperazic acid. One aspect of the present disclosure includes a transgenic microorganism (e.g., bacteria) engineered to accumulate piperazic acid and derivatives thereof, including a piperazic acid (Piz)-containing product. Another aspect of the present disclosure includes biochemical and biological methods for producing piperazic acid and derivatives thereof, including a piperazic acid (Piz)-containing product. Another aspect of the present disclosure includes compositions and methods of using isotopically labeled piperazic acid and derivatives thereof, including a piperazic acid (Piz)-containing product.